C. Bachert, V. Vovolis, P. Margari
Jul 1, 2001
Citations
0
Influential Citations
19
Citations
Quality indicators
Journal
Allergy
Abstract
Background: Mizolastine, a potent H1 antihistamine with additional antiallergic properties, is marketed for the treatment of allergic rhinoconjunctivitis and urticaria. The objective was to investigate the safety and effectiveness of mizolastine under conditions of daily practice in patients with seasonal allergic rhinoconjunctivitis (SAR).